BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Falcon 9 rocket launches Starlink satellites before making 550th SpaceX landing (video) - 2April full moon 2026 dazzles as 'Pink Moon' lights up skies worldwide (photos)
- 3Audits of 6 Specialty Mixed drinks
- 4Bavarian leader questions Germany's Eurovision participation
- 5The Most Compelling Innovation Developments Somewhat recently
- The Electric Bicycle Americans Can Confide in 2024
- Deaths reported in Lebanon as Israel and Hezbollah exchange attacks
- Instructions to Adjust Work, Life, and Seeking after a Web based Advertising Degree
- 3 moms, 3 countries, 1 very familiar problem: Why child care costs still don't add up for families
- 4 Dazzling And Well known Island Objections In US
- Step by step instructions to Pick A Keep money with High Fixed Store Loan costs
- Experience Is standing by: 10 Pleasant Setting up camp Areas to
- A definitive Manual for Picking Electric Vehicle: Decision in favor of Your Number one
- Glamour Shots once ruled the mall. I went to one of the last ones standing.
